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OBJECTIVES: To compare ocular surface changes induced via glaucoma treatment in patients using fixed
combinations of prostaglandin analogues (travoprost, latanoprost and bimatoprost) with 0.5% timolol maleate.
METHODS: A prospective, multicenter, randomized, parallel group, single-blind clinical trial was performed in 33
patients with ocular hypertension or open angle glaucoma who had not been previously treated. The ocular
surface was evaluated prior to and three months after treatment, with a daily drop instillation of one of the three
medications. The main outcome measurements included the tear film break-up time, Schirmer’s test, Lissamine
green staining, the Ocular Surface Disease Index questionnaire, impression cytology using HE and PAS and
immunocytochemistry for interleukin-6 and HLA-DR. Ensaiosclinicos.gov.br: UTN - U1111-1129-2872
RESULTS: All of the drugs induced a significant reduction in intraocular pressure. Decreases in the Schirmer’s test
results were observed with all of the drugs. Decreases in tear-film break-up time were noted with travoprost/
timolol and latanoprost/timolol. An increase in the Lissamine green score was noted with travoprost/timolol and
bimatoprost/timolol. The Ocular Surface Disease Index score increased after treatment in the travoprost/timolol
group. Impression cytology revealed a significant difference in cell-to-cell contact in the same group, an increase
in cellularity in all of the groups and an increase in the number of goblet cells in all of the groups. The fixed
combinations induced an increase in IL-6 expression in the travoprost/timolol group, in which there was also an
increase in HLA-DR expression.
CONCLUSIONS: All of the fixed combinations induced a significant reduction in intraocular pressure, and the
travoprost/timolol group showed increased expression of the inflammatory markers HLA-DR and interleukin-6.
All three tested medications resulted in some degree of deterioration in the ocular surface after three months of
glaucoma treatment.
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& INTRODUCTION
Glaucoma is a chronic, multifactorial, progressive optic
neuropathy that requires long-term treatment with topical
hypotensive medications (1). Several classes of drugs are
currently available to treat this condition, including pros-
taglandin (PG) analogues as well as fixed combinations
(FCs) of prostaglandin/prostamide analogues combined
with 0.5% timolol maleate (2).
Beta-blockers are often used to treat glaucoma and
were considered the ‘‘gold standard’’ for starting glau-
coma treatment until recently, when they were replaced
by prostaglandin analogues (2). Beta-blockers have
many systemic side effects, especially bradycardia and
bronchospasms, as well as effects on the central nervous
system.
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While the systemic side effects induced by topical PG
analogues are rare, iris hyperpigmentation, excessive eye-
lash growth and conjunctival hyperemia have been reported
among the local side effects caused by these drugs (3-5).
Conditions suggestive of the stimulation or reactivation of
ocular inflammatory responses, such as anterior uveitis or
cystoid macular edema, have also been associated with the
use of PG analogues (6).
Ocular surface dysfunction has also been related to
glaucoma treatment. Beta-blockers have been known to
induce conjunctival hyperemia, punctate keratitis and
corneal anesthesia, as well as dry eye and allergic
blepharoconjunctivitis (7-9).
Previous studies with patients who received long-term
treatment with topical medications showed that both
hypotensive drugs and their preservatives (especially
benzalkonium chloride – BAK) could increase the number
of inflammatory cells and fibroblasts in the substantia
propria of the conjunctiva and reduce the number of goblet
cells, thereby inducing ocular surface changes manifested
clinically as dry eye (8-11). The length of administration,
concentration and amount of these drugs have been related
to the severity of the side effects. In addition, there has been
strong evidence suggesting that these changes might
increase the risk of trabeculectomy failure (12,13).
However, most of the information on this subject was
published prior to the introduction of PG analogues.
The purpose of this study was to evaluate (clinically,
histologically and via immunocytochemistry) the ocular
surface changes induced by glaucoma treatment with
topical FCs of PG analogues and timolol.
& MATERIALS AND METHODS
Inclusion criteria
Eligible patients were adults ($18 years of age) with a
clinical diagnosis of primary open-angle glaucoma (POAG)
or ocular hypertension (OH) in at least one eye and with
no previous topical hypotensive treatment. The selected
patients had a open iridocorneal angle upon gonioscopy
examination. POAG was diagnosed on the basis of
characteristic optic disc changes and/or glaucomatous
visual field loss demonstrated on the Humphrey visual
field analyzer (HFA) (Humphrey Instruments, Inc., Zeiss
Humphrey, San Leandro, California, USA). IOP, measured
at 8 a.m., had to be between 26 mm Hg and 35 mm Hg in
the study eye(s). In addition, patients were required to have
a corrected distance visual acuity (CDVA) of 20/70 or better
in each eye, and those with glaucoma had to have a recent
(within three months) visual field examination showing a
mean deviation greater than -15 dB and no fixation threat.
Finally, the eligible patients were required to be able to
follow instructions, to be willing and able to attend all of the
study visits, and to provide informed consent prior to
screening.
Exclusion criteria
Patients were excluded if they met any of the following
criteria: previous ocular surgery; active ocular inflamma-
tion; or clinically diagnosed dry eye. Patients with hyper-
sensitivity or poor tolerance to any components of the study
medication; with bronchial asthma or history of bronchial
asthma; with bronchial hyperreactivity or severe chronic
obstructive pulmonary disease that would preclude the safe
administration of a topical beta-blocker; sinus bradycardia,
second-degree or third-degree atrioventricular block, sinoa-
trial block, overt cardiac failure, or cardiogenic shock that
would preclude the safe administration of a topical beta-
blocker; or a severe medical or psychiatric condition were
also excluded from the study.
A prospective, randomized, single-blind, multicenter,
parallel group, interventional study was conducted between
March 2009 and September 2010 at the Federal University of
Sa˜o Paulo (UNIFESP) in Sa˜o Paulo, Brazil.
The participants were allocated to each treatment group
following the sequence of a randomization table. The
randomization table was generated using software (Stata,
version 11, College Station, Texas, USA) and a block size of
three. The participants were enrolled and assigned to each
group by the study coordinator.
After the sample size was calculated, 33 patients were
selected (11 patients were randomly distributed into three
different groups according to medication regimen) by two
examiners (HR and NL) and were allocated using per-
muted-block randomization (block size = 3; allocation rate
1:1:1) into the following three groups, independently of age,
sex or residence: latanoprost+timolol (LT); bimatoprost+ti-
molol (BT); or travoprost+timolol (TT) (Figure 1).
The medications were administered once daily in the
evening for 12 weeks in selected patients in all of the
groups.
The clinical data collected included the patients’ demo-
graphic data (age, sex and ethnicity). All of the patients
underwent routine ophthalmological examinations prior to
and after three months of treatment. The ocular surface
evaluation included biomicroscopic examination of the lids,
conjunctiva, cornea and tear film. The diagnostic tests
included Schirmer’s test with anesthesia, Lissamine green
vital staining, tear film break-up time (TBUT) and impres-
sion cytology. The OSDI questionnaire was also applied.
After the ocular surface evaluation, intraocular pressure
(IOP) was measured with the Goldmann applanation
tonometer.
The patients were examined at two centers (Graefe
Institute of Ophthalmology and Brasilia Base Hospital),
following instructions provided by the Cornea and External
Disease Service in the Department of Ophthalmology,
UNIFESP. All of the IOP measurements were obtained at
the same time (8 a.m.). The rooms where the examinations
were performed had neither air conditioning nor windows,
and the air humidity and temperature were controlled
with specific equipment. Prior to the examination, the
patients rested for 20 minutes with the door to the room
closed. The tests were performed by two researchers (HR
and NL) and were analyzed at the Ocular Surface
Advanced Center (CASO) by two blinded investigators
(JB and PANF).
Those investigators who assessed the primary outcomes
of the study were blinded to the allocation status of the
participants. The statistician who performed the data
analysis was blinded to all information.
Dry eye was defined as a TBUT score of ,5 seconds (2%
fluorescein, Ophthalmos, Sa˜o Paulo, SP, Brazil), ,5 mm
wetting in the Schirmer’s test (Schirmer strips, Ophthalmos,
Sa˜o Paulo, SP, Brazil) with topical anesthesia (0.5% prox-
ymetacaine chlorohydrate, AnestalconH, Alcon Laborato´rios
do Brasil, Sa˜o Paulo, SP, Brazil) and corneal and conjunctival
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staining with 1% Lissamine green (Ophthalmos, Sa˜o Paulo,
SP, Brazil) $3 on the van Bijsterveld scale (0 to 9).
Impression cytology
After the ocular surface evaluation, all of the patients
were subjected to impression cytology (IC) sampling by two
researchers (HR and NL). Following topical anesthesia, IC
specimens were collected (HAWP 304, Millipore, Bedford,
Massachusetts, USA) from an exposed area of the bulbar
conjunctiva (temporal region) and an unexposed area of the
conjunctiva (superior region) adjacent to the corneal limbus.
All of the strips were processed for periodic acid Schiff and
Gill’s hematoxylin staining. Glass slides mounted with
Entellan (Merck, Darmstadt, Germany) were examined with
a blinded procedure under light microscopy by an
experienced professional (JNB). For quality control, only
IC specimens were included with at least one third of the
filter surface covered by visible epithelial cells. The
conjunctiva samples were evaluated according to estab-
lished techniques for the following parameters: cellularity;
cell-to-cell contact; nuclear-to-cytoplasmic (N/C) ratio;
nuclear chromatin; goblet cell density; keratinization; and
distribution of inflammatory cells. A score of 0 to 3 was
assigned to each of these features: 0 - normal findings; 1 -
borderline features; and 2 and 3 - abnormal features (29,30).
The total score for each sample was classified as A (normal;
total score 0-3), B (borderline; total score 4-6) or C
(abnormal; total score .6). The goblet cell densities were
considered normal when the cells were abundant, border-
line when there was a slightly or moderately reduced
number of cells and abnormal when there was a distinct
reduction in the number of cells (the presence of one or no
goblet cells).
Immunocytochemistry
Other conjunctival impression cytology samples were
obtained from the same areas as the first samples, using
Biopore membranes (Millicell-CM 0.4 mm PICM 012550,
Millipore Corp, Bedford, Massachusetts, USA), and were
immunostained with monoclonal antibodies to HLA-DR
and IL-6. The samples with cells covering more than 80% of
the membrane area or samples covering between 40% and
80% (where the cells were confluent and present in a
discrete area) were considered suitable for immunocytolo-
gical analysis. Samples with cellularity of less than 40%
were considered unsuitable. The number of cells positive for
HLA-DR and IL-6 and the total number of cells in five
adjacent microscopic high-power fields (40X) were counted
by the two masked observers (JNB and PANF). The results
for each phenotype were expressed as a percentage of the
total number of cells and were compared pre- and post-
treatment.
Figure 1 - Flow diagram of the progress through the phases of this parallel, randomized trial of three groups.
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Statistical analysis
The sample size calculation was based on a pilot study
performed at one of the study sites. Two principal out-
comes, the Schirmer’s test and impression cytology, were
selected for this purpose. To detect a difference of 3 mm (SD
2 mm) with the Schirmer’s test at two points in time (pre-
and post-treatment), a sample size of 10 was necessary to
obtain a power of 80% at the 5% significance level. This
sample size (N= 10) would provide a power of 94% to detect
a difference of 0.4 cells (SD 0.2 cells) in the mean number of
cells in the impression cytology test. Therefore, a sample
size of 11 per treatment group was used in this study.
The Kolmogorov-Smirnov (K-S) test was used to deter-
mine whether the continuous variables had a normal
distribution. One-way ANOVA with a significance level of
5% was used to compare the continuous variables, and the
Kruskal-Wallis test was used to compare the continuous
variables with a non-Gaussian distribution. When statisti-
cally significant differences were found, the data were
further analyzed using post hoc comparisons with Fisher’s
exact test (for comparisons of up to three groups) or the
Tukey-Kramer test (comparisons of more than three groups)
for p-value correction. The calculations were performed
with StatView statistical software (SAS Institute Inc., Cary,
North Carolina, USA). The level of statistical significance
was set at p= 0.05.
Ethics
The study was approved by the UNIFESP Medical Ethics
Committee (reference no. 0954/06) and was registered with
an internationally accredited site (UTN U1111-1129-2872;
RBR-7mmp6k- www.ensaiosclinicos.gov.br) in accordance
with the guidelines set forth in the Declaration of Helsinki.
All of the patients provided informed consent. The research
was funded by the Federal University of Sa˜o Paulo/
FAPESP.
& RESULTS
The results of the statistical analysis were unaffected by
the demographic data (age, sex and ethnicity) (Table 1).
All three combinations (LT, BT and TT) produced a
statistically significant reduction in IOP (p=0.0001). The mean
IOP for the TT group was 24.72¡1.03 mm Hg (95% CI 22.66-
26.78) prior to treatment and 14.00¡0.44 mm Hg (95% CI
13.12-14.88 mmHg) after treatment; the corresponding figures
for the BT group were 22.32¡5.58 mm Hg (95% CI 11.16-
33.48) and 12.10¡2.96 mm Hg (95% CI 6.18-18.02), respec-
tively, and for the LT group, they were 20.32¡4.99 mm Hg
(95% CI 10.34-30.3) and 11.59¡3.11 mmHg, respectively (95%
CI 5.37-17.81).
The ocular surface evaluations revealed a significant
decrease in the Schirmer’s test values for the patients treated
with all of the drugs: the mean value for the TT group was
8.95¡0.21 mm (95% CI 8.53-9.37) prior to treatment and
7.18¡0.73 mm (95% CI 5.72-8.64) after treatment (p=0.0001);
the corresponding figures for the LT group were
13.77¡4.72 mm (95% CI 4.33-23.21) and 9.09¡3.65 mm
(95% CI 1.79-16.39) (p= 0.0007), respectively, and they were
12.45¡3.85 mm (95% CI 4.75-20.15) and 9.95¡3.68 mm (95%
CI 2.59-17.31) (p=0.0333), respectively, for the BT group.
The TBUT decreased significantly in the TT and LT
groups. The mean values for the former were 11.95¡1.49
seconds (95% CI 8.97-14.93) prior to treatment and
9.54¡0.85 seconds (95% CI 7.84-11.24) after treatment
(p,0.0001), and for the latter, the values were 13.86¡3.18
seconds (95% CI 7.5-20.22) and 11.68¡3.38 seconds (95% CI
4.92-18.44), respectively (p= 0.0025). For the BT group, the
difference was not statistically significant (p= 0.45).
Scores for Lissamine green staining increased signifi-
cantly in patients treated with TT (mean score of 2.36¡0.65
[95% CI 1.06-3.66] prior to treatment and 6¡0.01 [95% CI
5.98-6.02] after treatment [p,0.0001]) and with BT (mean
score of 2¡1.48 [95% CI 0.94-4.96] prior to treatment and
3.27¡1.45 [95% CI 0.37-6.17] after treatment [p= 0.0007]).
For the LT group, this difference was not statistically
significant (p= 0.22).
The OSDI scores increased in all of the groups, but the
difference was only significantly different in the TT group
(mean score 33.74¡6.88 [95% CI 19.98-47.5] prior to
treatment and 39.94¡3.92 [95% CI 32.1-47.78] after treat-
ment [p= 0.02]). All of the groups could be classified as
having mild to moderate dry eye on the OSDI scale.
Table 2 summarizes the clinical ocular surface data for the
three groups.
Impression cytology
Although the total score (histological classification) was
worse for all of the groups after treatment, this change was
not statistically significant. However, when specific IC
parameters were considered, an increase in cellularity could
be observed in all of the groups: TT - 0.04¡0.30 cells (95%
CI -0.56-0.64) prior to treatment and 0.386¡0.58 cells (95%
CI -0.774-1.546) after treatment (p= 0.0008); BT - 0.27¡0.66
(95% CI -1.05-1.59) and 0.70¡0.82 cells (95% CI -0.94-2.34)
prior to and after treatment, respectively (p= 0.008); and LT -
0.182¡0.54 (95% CI -1.498-1.862) and 0.545¡0.85 cells (95%
CI -1.155-2.245) prior to and after treatment, respectively
(p= 0.0022).
The TT group had 0.29¡0.63 goblet cells (95% CI -0.97-
1.55) prior to treatment and 0.86¡0.93 cells (95% CI -1.0-
2.72) after treatment (p= 0.012). For the BT group, the
Table 1 - Demographic data: age, sex and ethnicity.
TT group BT group LT group p-value
Age (mean¡sd) 61.9¡6.91 60.5¡4.61 63.65¡5.12 p.0.05
Ethnicity
White caucasian 3 4 3 p.0.05
African american 1 1 1 p.0.05
Hispanic 7 5 6 p.0.05
Asian 0 1 1 p.0.05
Sex (male:female) (4:7) (5:6) (6:5) p.0.05
* There were significant differences between African American and Asian patients, compared with Caucasians and Hispanics, but not between the African
American and Asian groups or between the Caucasian and Hispanic groups, respectively.
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corresponding figures were 0.57¡0.873 (95% CI -1.176-
2.316) and 0.93¡0.873 (95% CI -0.816-2.676) (p= 0.054) and
0.182¡0.54 (95% CI -0.898-1.262) and 0.545¡0.85 (95% CI -
1.155-2.245) (p= 0.0186) for the LT group, respectively.
The mean cell-to-cell contact was 0.136¡0.40 (95% CI -
0.664-0.936) in the TT group prior to treatment and
0.59¡0.73 (95% CI -0.87-2.05) after treatment (p= 0.0005).
For the BT group, the mean values were 0.27¡0.54 (95% CI -
0.81-1.35) and 0.41¡0.58 (95% CI -0.75-1.57) prior to and
after treatment (p=0.26), respectively, and for the LT group,
the corresponding values were 0.16¡0.43 (95% CI -0.7-1.02)
and 0.38¡0.66 (95% CI -0.94-1.7), respectively (p= 0.07).
There were no changes in inflammatory cells, keratiniza-
tion or N/C ratio (Table 3).
Immunocytochemistry
While TT induced a statistically significant increase in
HLA-DR expression (the mean count of cells positive for
HLA-DR in the TT group was 39.5¡70.56 [95% CI -101.62-
180.62] prior to treatment and 88.77¡116.28 [95% CI -143.79-
321.33] after treatment (p= 0.0184) [Figure 2]), BT and LT
showed a decrease in HLA-DR expression that was not
statistically significant for either group (BT, p= 0.26; LT,
p= 0.92).
Similarly, TT induced a significant increase in IL-6-
positive cells (Figure 3): the mean count was 58.48¡91.70
(95% CI -124.92-241.88) prior to treatment and 150.52¡
171.31 (95% CI -192.1-493.14) after treatment (p= 0.0023). BT
and LT also showed an increase in HLA-DR expression, but
this increase was not statistically significant for either group
(BT, p= 0.33; LT, p= 0.33).
& DISCUSSION
All three medications produced a statistically significant
reduction in IOP, with no difference among them. Our
results were similar to those described by Centofanti et al.
regarding fixed combinations (14).
Impaired tear film production associated with glaucoma
treatment has been described in many articles (8,10).
Strong evidence provided by previous clinical and
experimental studies has indicated that the chronic use of
antiglaucoma drugs might induce ocular surface changes,
causing discomfort at instillation, conjunctival inflamma-
tion, tear film instability, subconjunctival fibrosis, apoptosis
of conjunctival epithelial cells and corneal surface changes
(15-17).
These changes could result in a greater risk of failure
when patients undergo antiglaucoma surgery, particularly
trabeculectomy, as a result of postoperative fibrosis
(9,12,13).
In the present study, we observed that all three drugs
induced a subclinical inflammatory reaction. This reaction
was only detected via immunocytochemistry, which
revealed cells positive for inflammatory markers, such as
IL-6 and HLA-DR. No increase in inflammatory cells was
detected via IC.
Subclinical inflammation associated with the use of
latanoprost has been reported by other authors who, using
histopathology and immunohistochemical markers (HLA-
DR, IL-6 and IL-8), have described a strong correlation
between dry eye and inflammatory cells in the conjunctival
epithelium and substantia propria (15,17,18).
Immunocytochemistry after three months of treatment
did not reveal any changes in total score. However, we
observed changes in other related parameters, such as
cellularity, number of goblet cells and cell-to-cell contact.
The increase in cellularity without an inflammatory reaction
was likely related to reactive hyperplasia of the conjunctival
epithelial cells in response to the toxic effects of the drugs.
Authors such as Guenoun et al. have correlated the
increase in goblet cells induced by PG analogues with a
possible protective effect against BAK-induced toxicity to
the ocular surface (19). In a previous study, we also
observed an increase in the number of goblet cells in groups
treated with PG analogues (latanoprost, travoprost and
bimatoprost), but this increase was not sustained over six
months (15,18,20). This effect has been controversial;
hyperplasia in goblet cells seems to represent a protective
mechanism in the initial phase of chronic aggression to the
ocular surface, as observed in allergies or responses to
pollution, but it is followed by a decrease in the number of
these cells if the aggressive factor becomes chronic (21,22).
Changes in cell-to-cell contact result in a loss of ‘‘gap
junctions’’ and in edema, which are reflected in the
epithelial architecture and which lead to keratopathy.
These pathological changes in the ocular surface could
partly explain the occurrence of dry eye symptoms in
patients using hypotensive drugs.
Herrera et al. reported that prolonged use (longer than six
months) of 0.5% timolol maleate might lead to a higher
incidence of dry eye, with lower TBUT values and
Schirmer’s test scores (7). Several reports have also demon-
strated that timolol could cause a decrease in the number of
goblet cells and keratoconjunctivitis sicca (7,8,13).
Reductions in TBUT values and Schirmer’s test scores have
been described in many studies investigating the effects of
the length of glaucoma treatment, the number of medica-
tions used and preservative concentrations (16,23,24).
Table 2 - Clinical data prior to and three months after treatment with a fixed combination of travoprost 0.004%/timolol
0.5%, bimatoprost 0.03%/timolol 0.5% or latanoprost 0.005%/timolol 0.5% in naı¨ve patients; n = 33.
Travatan/Timolol Bimatoprost/Timolol Latanoprost/Timolol
pre-treatment
(mean¡SD)
post-treatment
(mean¡SD) p-value
pre-treatment
(mean¡SD)
post-treatment
(mean¡SD) p-value
pre-treatment
(mean¡SD)
post-treatment
(mean¡SD) p-value
Schirmer 8.95¡0.21 7.18¡0.73 0.00 12.45¡3.85 9.95¡3.68 0.03 13.77¡4.72 9.09¡3.65 0.00
TBUT 11.95¡1.49 9.54¡0.85 0.00 11.90¡3.22 11.18¡3.21 0.45 13.86¡3.18 11.68¡3.38 0.00
LGT 2.36¡0.65 6.00 ,0.001 2.00¡1.48 3.27¡1.45 0.00 0.86¡1.12 1.41¡1.71 0.22
OSDI 33.74¡6.88 39.94¡3.92 0.02 29.76¡15.93 30.30¡17.17 0.94 8.06¡7.10 11.16¡11.59 0.47
HLA-DR 39.50¡70.56 88.77¡116.28 0.02 126.86¡149.20 95.79¡108.01 0.26 176.79¡185.95 172.95¡167.09 0.92
IL-6 54.48¡91.70 150.52¡171.31 0.00 93.97¡124.17 120.59¡130.13 0.33 171.75¡126.28 198.16¡128.65 0.33
IOP 24.72¡1.03 14.00¡0.44 0.00 22.32¡5.58 12.10¡2.96 0.00 20.32¡4.99 11.59¡3.11 0.00
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In the present study, conjunctival function and tear film
stability were worse after treatment, indicating deterioration
of the ocular surface.
More recently, some authors have used the OSDI (Ocular
Surface Disease Index) questionnaire, a useful tool for
analyzing symptoms of dry eye, to measure symptoms in
glaucoma patients; the lower the OSDI score is, the less toxic
the medication is (24,26). In our study, OSDI scores also
showed an increase, with most patients having mild or
moderate dry eye, confirming the involvement of the lacrimal
functional unit and the ocular surface. Preservative-free
medications have been associated with lower scores, and
improvements in scores have been reported for patients who
switched to this type of medication (25,26).
One of the limitations in our study was related to ethnicity.
The numbers of Asian and African American individuals
distributed among the groups were considerably fewer than
those of Caucasian and Hispanic individuals; this could have
been a source of bias. Additionally, it should be noted that, in
our study, a large variation was observed in patients treated
with travoprost+timolol. Although the results were consid-
ered ‘‘normal,’’ this regimen group began with somewhat
worse ocular surface conditions, compared with the other
groups. Therewas a trend that was not statistically significant
toward a poorer ocular surface, irrespective of sex or age, at
the beginning of the study. This finding occurred by chance
and was likely related to the randomization method
(permuted-block) used to ensure sample balance, but it could
lead to selection bias in a non-masked study. This trend was
only noticed after the investigation was completed. For this
reason and because of the short study period, we excluded
comparisons among the three drugs.
The number of patients remaining after all of the
exclusion criteria were applied was somewhat modest
(n = 11 per group) for a multicentric study, but it was
substantial for a two-center investigation. Thus, we assert
that our results can be extrapolated and are applicable for
general ophthalmic clinics, particularly for glaucoma and
cornea specialists, as well as for large multicenter studies.
In summary, this study demonstrated that there were
significant changes in the ocular surface after exposure to
FCs for a short period (three months), despite the ease of
administration (once daily), and reduced exposure to
preservatives (one drop versus three if the medications
were administered individually). However, it cannot be
concluded from the present study whether any particular
drug induced greater changes in the ocular surface.
& ACKNOWLEDGMENTS
This study was supported by the Federal University of Sa˜o Paulo and
Fundac¸a˜o de Amparo a` Pesquisa do Estado de Sa˜o Paulo (FAPESP).
Table 3 - Impression cytology scores. Several parameters were analyzed, but significant differences after three months
of treatment were only found in: (a) cell-to-cell contact in the TT group; (b) cellularity in all of the groups; and (c)
number of goblet cells in the TT and LT groups. NC: not counted.
Travoprost+Timolol Bimatoprost+Timolol Latanoprost+Timolol
Pre Post p-value Pre Post p-value Pre Post p-value
Keratinization NC NC NC NC NC NC
Cell-to-cell Contact (a) 0.136 0.591 0.0005 0.273 0.409 0.26 0.159 0.381 0.067
Inflammatory cells NC NC NC NC NC NC
Cellularity (b) 0.045 0.386 0.0008 0.273 0.705 0.008 0.114 0.545 0.0022
Goblet cells (C) 0.295 0.864 0.0012 0.568 0.932 0.0541 0.182 0.545 0.0186
N/C ratio NC NC NC NC NC NC
Figure 2 - HLA-DR expression. On the left: images of the
travatan+timolol group pre-treatment, with cells negative for
HLA. On the right: the same group after treatment, at 1006 (on
the top) and 4006 (on the bottom) magnification, respectively.
Figure 3 - IL-6 expression. Top images: on the left, the
bimatoprost+timolol group pre-treatment, with cells negative
for IL-6. On the right: the same group after treatment, with 2006
magnification. The figures on the bottom show the same images
as above, with 4006magnification. Note the increase in positive
cells after treatment (images on the right).
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